UBS AM
TIL icon

UBS AM’s Instil Bio TIL Stock Holding History

UBS AM’s Portfolio TIL Stock Details TIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-10,098
Closed -$933K – 2774
2022
Q2 		$933K Sell
10,098
-397
-4% -$56.2K ﹤0.01% 2004
2022
Q1 		$2.26M Sell
10,495
-849
-7% -$198K ﹤0.01% 1743
2021
Q4 		$3.88M Sell
11,344
-235
-2% -$90.7K ﹤0.01% 1532
2021
Q3 		$4.14M Sell
11,579
-319
-3% -$119K ﹤0.01% 1450
2021
Q2 		$4.6M Buy
+11,898
New +$4.41M ﹤0.01% 1410

Other funds holding TIL

CVV
Curative Ventures V Dallas, Texas $15.6M AUM 52.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CI
CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

UBS AM's TIL Position: Q3 2022 in Review

UBS AM sold out of Instil Bio (TIL) in Q3 2022, closing a stake of 10,098 shares — an estimated $933K sold.

UBS AM first reported a position in TIL in Q2 2021 and held it in 5 quarters. The position peaked at $4.6M in Q2 2021. 95 funds tracked by Wall St. Rank hold TIL as of Q3 2022.

  • UBS AM reported no remaining Instil Bio position as of Q3 2022 after selling out during the quarter.
  • UBS AM sold 10,098 Instil Bio shares in Q3 2022, an estimated $933K.
  • UBS AM first reported a position in Instil Bio in Q2 2021 and held it in 5 quarters.
  • UBS AM's Instil Bio position peaked at $4.6M in Q2 2021.
  • 95 funds tracked by Wall St. Rank held Instil Bio as of Q3 2022.

Based on UBS AM's 13F filing for Q3 2022, filed 14 Nov 2022.